CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.120
-0.170 (-3.96%)
At close: Apr 28, 2026, 4:00 PM EDT
4.289
+0.169 (4.10%)
After-hours: Apr 28, 2026, 7:09 PM EDT
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 12.1, with a low estimate of 5.00 and a high estimate of 17. The average target predicts an increase of 193.69% from the current stock price of 4.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 23, 2026.
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $12 | Buy | Maintains | $10 → $12 | +191.26% | Mar 23, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $16 | Buy | Maintains | $10 → $16 | +288.35% | Mar 19, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $8 → $16 | Strong Buy | Maintains | $8 → $16 | +288.35% | Mar 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +264.08% | Mar 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $6 → $11 | Buy | Maintains | $6 → $11 | +166.99% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
24.63M
from 76.20M
Decreased by -67.68%
Revenue Next Year
26.50M
from 24.63M
Increased by 7.61%
EPS This Year
-0.46
from -0.15
EPS Next Year
-0.51
from -0.46
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 84.0M | 88.9M | ||||||
| Avg | 24.6M | 26.5M | ||||||
| Low | 3.9M | 2.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.2% | 261.1% | ||||||
| Avg | -67.7% | 7.6% | ||||||
| Low | -94.9% | -92.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.20 | -0.18 | ||||||
| Avg | -0.46 | -0.51 | ||||||
| Low | -0.75 | -0.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.